Lonza Group AG (LZAGF.PK), a Swiss multinational manufacturing company that operates as a contract development and manufacturing organization (CDMO) for the pharmaceutical, biotech, and nutrition industries, confirmed its full-year 2025 Outlook for both its CDMO and Capsules & Health Ingredients or CHI businesses.
The CDMO business is on track to deliver higher sales in the second half compared to the first, along with a healthy progression of CORE EBITDA in line with the 2025 Outlook. This outlook was upgraded in the Half-Year 2025 results to constant exchange rate (CER) sales growth of 20 to 21 percent, previously described as "approaching 20 percent," and a CORE EBITDA margin of 30 to 31 percent, previously "approaching 30 percent."
Excluding Vacaville—which is expected to contribute at the upper end of around half a billion Swiss francs in sales at a better-than-expected margin in 2025—Lonza anticipates low-teens percentage organic CER sales growth and margin improvement in its CDMO business, consistent with its CDMO Organic Growth Model.
Lonza also confirms its Full-Year 2025 Outlook for the CHI business, expecting low-to-mid single-digit percentage CER sales growth and an improved CORE EBITDA margin in the mid-twenties.
In its qualitative update for the third quarter of 2025, Lonza reported strong performance in its CDMO business, aligned with the upgraded Full-Year Outlook. The Capsules and Health Ingredients (CHI) segment continued its anticipated recovery and returned to growth, also in line with the Full-Year 2025 Outlook.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.